echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > East China Pharmaceuticals introduces dual-specific antibody PRV-3279 for development rights and interests in Greater China

    East China Pharmaceuticals introduces dual-specific antibody PRV-3279 for development rights and interests in Greater China

    • Last Update: 2021-02-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    PRV-3279 is a humanized dual antibody (a DART® dual-specific antibody for B cell surface proteins CD32B and CD79B.
    in combination with CD32B and CD79B triggers inhibition of B cell function and autoantibodies, thus regulating B cells without causing B cell depletion.
    Bio is developing PRV-3279 to block systemic lupus erythematosus (SLE), which is in Phase I in the United States.
    SLE is a chronic autoimmune disease characterized by over-active B cells and pathological production of autoantibodies.
    PRV-3279 also has the potential to prevent or reduce immunogenicity (including, but not limited to, gene therapy vectors and genetically modified organisms) in biological therapy, in the preclinical stage.
    Under the terms of the agreement, Provention Bio will receive an advance of $6 million from East China Pharmaceuticals and $11.5 million over the next three years to advance research and development and production of the PRV-3279, with future milestone payments of up to $172 million upon registration and commercial milestones.
    Product Bio will also receive a tiered, double-digit net sales fee.
    East China Pharmaceuticals will be responsible for the clinical development and commercialization of PRV-3279 in Greater China (including Chinese mainland, Hong Kong, Macau and Taiwan), and the two companies will establish a joint steering committee.
    DevelopmentBio will continue to be responsible for the clinical development and commercialization of prV-3279 in the United States and other regions.
    note: There are deletions in the original text
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.